Regeneron Pharmaceuticals: Strength in Science

In 2021, Regeneron Pharmaceuticals attracted the active attention of investors with its victories in the anti-cancer struggle. Now Regeneron Pharmaceuticals no longer sells its famous anti-coronavirus “cocktail” REGEN-COV, but retains the same strong market position.

In January of this year, the FDA in the United States suspended the license for the use of REGEN-COV in the treatment of the Omicron strain, as it recognized it as ineffective. In other cases, this would have led to the collapse of securities, but not here – long before covid, Regeneron had a strong market position with its seven popular drugs.

The strengths of Regeneron’s business in the second quarter of 2022:

• revenue and adjusted net profit fell, but were better than expected: revenue was $2.86 billion (-44.4% YoY), ESP $9.77 per share (above forecasts). The drop in revenue may be due to the high base of the same period last year, when the cocktail was actively sold;
• Eylea revenue of $1.62 billion (+14% YoY), Dupixent sales of $2.09 billion (+40% YoY);
• prospects of the drug Dupixent. Indications for use have been expanded here, including for complicated asthma of children; in June, the drug was approved for the treatment of atomic dermatitis in children under 5 years old.

Overall, the business looks perfectly balanced and stable.

Even when the coronavirus begins to recede, Regeneron will focus on other drugs.

The consensus forecast for Regeneron Pharmaceuticals paper is $780.

The MACD indicator on the daily chart is declining in the positive zone, but the buy signal remains in force. The Stochastic oscillator falls into the negative zone and signals a sale. Technical signals on the daily chart look mixed due to market conditions.